| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/06/2022 | 73.63% | BTIG | → $27 | Upgrades | Neutral → Buy |
| 08/16/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 02/11/2022 | 54.34% | BTIG | → $24 | Initiates Coverage On | → Buy |
| 07/26/2021 | 92.93% | Evercore ISI Group | → $30 | Initiates Coverage On | → Outperform |
| 07/26/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/26/2021 | 47.91% | Wedbush | → $23 | Initiates Coverage On | → Outperform |
| 07/26/2021 | 35.05% | Jefferies | → $21 | Initiates Coverage On | → Buy |
What is the target price for Aerovate Therapeutics (AVTE)?
The latest price target for Aerovate Therapeutics (NASDAQ: AVTE) was reported by BTIG on December 6, 2022. The analyst firm set a price target for $27.00 expecting AVTE to rise to within 12 months (a possible 73.63% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aerovate Therapeutics (AVTE)?
The latest analyst rating for Aerovate Therapeutics (NASDAQ: AVTE) was provided by BTIG, and Aerovate Therapeutics upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Aerovate Therapeutics (AVTE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aerovate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aerovate Therapeutics was filed on December 6, 2022 so you should expect the next rating to be made available sometime around December 6, 2023.
Is the Analyst Rating Aerovate Therapeutics (AVTE) correct?
While ratings are subjective and will change, the latest Aerovate Therapeutics (AVTE) rating was a upgraded with a price target of $0.00 to $27.00. The current price Aerovate Therapeutics (AVTE) is trading at is $15.55, which is within the analyst's predicted range.